Fertility News and Research

RSS

EGFR-targeted therapy improves survival rates in metastatic colorectal cancer patients

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today announced that Erbitux® (cetuximab) demonstrated a significant improvement in overall survival (OS) when added to standard 1st-line chemotherapy for metastatic colorectal cancer (mCRC) patients with KRAS wild-type tumors.

23 Sep 2009

FCI to educate women about fertility preservation

Life-saving cancer treatments such as chemotherapy and radiation can destroy the reproductive potential of both men and women; an added struggle for the 130,000 people in the US diagnosed with cancer each year. The good news is that advances in fertility technologies now give patients the ability to preserve their fertility prior to treatment, an option many oncologists fail to inform their patients.

23 Sep 2009

Swedish researcher to receive Fernström Foundation's Nordic Prize

Internationally renowned Swedish researcher Professor Jan-Åke Gustafsson, from KI and the University of Houston, is this year's recipient of the Fernström Foundation's Nordic Prize. The prize, which is worth SEK 1 million, is one of Scandinavia's most prestigious medical prizes.

21 Sep 2009

PROLOR Biotech initiates Phase I clinical trial of its human growth hormone drug candidate

PROLOR Biotech, Inc. (OTC Bulletin Board: PBTH) formerly Modigene Inc., today announced the initiation of a Phase I clinical trial of its long-acting human growth hormone drug candidate hGH-CTP.

21 Sep 2009

Two-day forum addresses maternal, child mortality in Asia-Pacific region

Poor health care, gender inequality, violence and poverty are to blame for Asian-Pacific countries' failure to significantly reduce maternal and child mortality rates in the region, Noeleen Heyzer, executive secretary of the Economic and Social Commission for Asia and the Pacific (ESCAP), said during the Asia-Pacific Forum on International Conference on Population and Development in Bangkok.

18 Sep 2009

Health reform bill may limit tax-free flexible spending accounts

NASDAQ/Dow Jones reports: "Employees who enjoy unlimited tax-free treatment of out-of-pocket medical expenses through employee-benefit plans could be facing new curbs on the tax subsidy in health-care overhaul legislation.

17 Sep 2009

ESHRE's workshop on cryobiology

ESHRE invites you to attend its workshop on freezing of human sperm, eggs and embryos in Athens, Greece "Cryobiology and cryopreservation of human gametes and embryos". The workshop provides a forum for clinicians and scientists to share research results and discuss problems and new developments.

17 Sep 2009

ESHRE's first workshop on male infertility

ESHRE invites you to attend its first workshop on male infertility in Thessaloniki, Greece "Reproductive andrology: linking laboratory to clinical practice". The workshop provides a forum for clinicians and scientists to share research results and discuss new developments.

16 Sep 2009

ESHRE workshop on human reproduction, more specifically on the freezing of sperm and embryos

ESHRE invites you to attend its workshop on freezing of human sperm, eggs and embryos in Athens, Greece "Cryobiology and cryopreservation of human gametes and embryos".

16 Sep 2009

Defective gene is linked to male infertility

Virginia Commonwealth University School of Medicine researchers have discovered a gene involved with the production of sperm that may contribute to male infertility and lead to new approaches to male contraception.

16 Sep 2009

IntegraMed’s Attain IVF Program now offered at Dallas IVF

IntegraMed America, Inc. (NASDAQ: INMD), the nation’s leading provider of specialty healthcare services in emerging, technology-focused niches, today announced that Dallas IVF has begun offering IntegraMed’s Attain™ IVF Program, a course-of-treatment financing program that improves patient success rates with in vitro fertilization (IVF) fertility treatments.

14 Sep 2009

Phase III STARTMRK clinical study on ISENTRESS in comparison to efavirenz

ISENTRESS , an integrase inhibitor from Merck & Co., Inc., was studied in comparison to efavirenz in maintaining viral load suppression to undetectable levels (less than 50 copies/mL) and at improving CD4 cell counts in previously untreated (treatment-naïve) HIV-1-infected patients through 96 weeks in a Phase III study called STARTMRK.

14 Sep 2009

Abstracts on Merck Serono oncology treatments to be presented at ECCO and ESMO

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, continues to drive the global effort to ensure patients receive personalized cancer therapies. A total of 17 abstracts concerning Merck Serono oncology treatments will be presented at the joint 15th Congress of the European Cancer Organisation (ECCO) and 34th Congress of the European Society for Medical Oncology (ESMO), to be held in Berlin from 20-24 September 2009.

11 Sep 2009

Merck update on the status of telcagepant clinical development programs

Merck & Co., Inc. today updated the status of the clinical development programs for telcagepant (MK-0974) and MK-3207, the Company's investigational oral calcitonin gene-related peptide (CGRP) receptor antagonists for the intermittent treatment of acute migraine.

11 Sep 2009

Vitro Diagnostics' novel stem cell technology for cancer treatment

Vitro Diagnostics, Inc., dba Vitro Biopharma, announced advances in its adult stem cell products and technology with application to cell-based therapy of cancer. With the passing of Senator Edward Kennedy from brain cancer, we are reminded of such aggressive cancers without effective treatment.

10 Sep 2009

Research reveals genetic conversation between X and Y chromosomes

In the week that the University of Leicester celebrates the 25th anniversary of the discovery of DNA fingerprinting (Thursday September 10) new findings from the world-renowned University of Leicester Department of Genetics reveal for the first time that the male and female do truly communicate -at least at the fundamental genetic level.

10 Sep 2009

Merck's GARDASIL receives approval from FDA Advisory Committee

Merck & Co., Inc. announced today that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee agreed that efficacy, immunogenicity and safety data from clinical trials in males support the use of GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] in boys and men 9 through 26 years of age for the prevention of genital warts caused by human papillomavirus (HPV) types 6 and 11.

10 Sep 2009

Tel Aviv University biologist discusses about human fertility

About 10% of all couples hoping for a baby have fertility problems. Environmentalists say pollution is to blame and psychiatrists point to our stressful lifestyles, but evolutionary biologist Dr. Oren Hasson of Tel Aviv University's Department of Zoology offers a different take. The reproductive organs of men and women are currently involved in an evolutionary arms race, he reports in a new study. And the fight isn't over yet.

8 Sep 2009

Y chromosome may be responsible for a range of sex disorders

The unique mechanism behind the evolutionary survival of the human Y chromosome may also be responsible for a range of sex disorders, from failed sperm production to sex reversal to Turner Syndrome.

3 Sep 2009

Vitro Diagnostics develops technology and products for cell-based cancer therapy

Vitro Diagnostics, Inc. (OTCBB: VODG), dba Vitro Biopharma, announced advances in its adult stem cell products and technology with application to cell-based therapy of cancer. With the passing of Senator Edward Kennedy from brain cancer, we are reminded of such aggressive cancers without effective treatment.

2 Sep 2009